Hydrocortisone in very preterm infants does not improve rates of bronchopulmonary dysplasia and mortality

1. There were no significant differences in rates of bronchopulmonary dysplasia (BPD) and mortality at 36 weeks’ postmenstrual age (PMA) as a composite outcome in ventilator-dependent very preterm infants who received systemic hydrocortisone versus placebo. However, mortality at 36 weeks’ PMA as an individual outcome, was significantly lower in infants receiving hydrocortisone. Evidence Rating: Level […]